Probiotics with antimicrobial activity against multidrug resistant pseudomonas aeruginosa and acinetobacter baumannii

Korean Journal of Microbiology

Volumn 49, Issue 3, 2013, Pages 245-252

  Lee, Do Kyung ^a   Kim, Min Ji ^a   Kang, Joo Yeon ^b   Park, Jae Eun ^b   Shin, Hea Soon ^b   Ha, Nam Joo ^a  

^a Sahmyook University   (South Korea)

^b Duksung Women's University   (South Korea)

Author keywords

Antimicrobial activity; Bifidobacterium; Multidrug resistant Acinetobacter baumannii; Multidrug resistant Pseudomonas aeruginosa

Indexed keywords

EID: 84890231853     PISSN: 04402413     EISSN: None     Source Type: Journal    
DOI: 10.7845/kjm.2013.3048     Document Type: Article

References (38)

1. Ahn, J.B. 2005. Isolation and characterization of Bifidobacterium producing exopolysaccharide. Food Eng. Prog. 9, 291-296.
2. Anand, S.K., Srinivasan, R.A., and Rao, L.K. 1985. Antimicrobial activity associated with Bifidobacterium bifidum-II. Cult. Dairy Products J. 20, 21-23.
3. Ballongue, J. 1998. Bifidobacteria and probiotic action. pp. 519-587. In Salminen, S. and Von Wright, A. (eds.), Lactic Acid Bacteria: Microbiology and Functional Aspects. Marcel Dekker, New York, USA.
4. Bassetti, M., Righi, E., Esposito, S., Petrosillo, N., and Nicolini, L. 2008. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 3, 649-660.
5. Cheikhyoussef, A., Pogori, N., Chen, W., and Zhang, H. 2008. Antimicrobial proteinaceous compounds obtained from bifidobacteria: From production to their application. Int. J. Food Microbiol. 125, 215-222.
6. Chevalier, P., Roy, D., and Ward, D. 1990. Detection of Bifidobacterium species by enzymatic methods. J. Appl. Bacteriol. 68, 619-624.
7. Clinical and Laboratory Standards Institute (CLSI). 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard, 9th ed. CLSI document M07-A79, CLSI, Wayne, PA, USA.
8. De Vuyst, L., Avonts, L., and Makras, L. 2004. Probiotics, prebiotics and gut health. pp. 416-482. In Remacle, C. and Reusens, B. (eds.), Functional Foods, Ageing and Degenerative Disease. Woodhead Publishing, Cambridge, UK.
9. Deplano, A., Denis, O., Poirel, L., Hocquet, D., nonhoff, C., Byl, B., Nordmann, P., Vincent, J.L., and Struelens, M.J. 2005. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43, 1198-1204.
10. Falagas, M.E., Bliziotis, I.A., Kasiakou, S., Samonis, G., Athanassopoulou, P., and Michalopoulos, A. 2005. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis. [5,] 24 doi:10.1186/1471-2334-5-24.
11. Falagas, M.E. and Kopterides, P. 2006. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J. Hosp. Infect. 64, 7-15.
12. Fuller, R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66, 365-378.
13. Gaynes, R. and Edwards, J.R. 2005. National nosocomial infections surveillance system. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41, 848-854.
14. Gibson, G.R. and Wang, X. 1994. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J. Appl. Bacteriol. 77, 412- 420.
15. Gill, H.S. and Guarner, F. 2004. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80, 516-526.
16. Gomes, A.M.P. and Malcata, F.X. 1999. Bifidobacterium spp. and Lactobacillus acidophilus: Biological, biochemical, technological and therapeutical properties relevant for use as probiotics. Trends Food Sci. Technol. 10, 139-157.
17. Guarner, F. and Malagelada, J.R. 2003. Gut flora in health and disease. Lancet 361, 512-519.
18. Gupta, V. and Garg, R. 2009. Probiotics. Indian J. Med. Microbiol. 27, 202-209.
19. Hammes, W.P. and Tichaczek, P.S. 1994. The potential of lactic acid bacteria for the production of safe and wholesome food. Z. Lebensm. Unters. Forsch. 198, 193-201.
20. Hentges, D.J., Stein, A.J., Casey, S.W., and Que, J.U. 1985. Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: influence of antibiotics on colonization resistance. Infect. Immun. 47, 118-122.
21. Iannitti, T. and Palmieri, B. 2010. Therapeutical use of probiotic formulations in clinical practice. Clin. Nutr. 29, 701-725.
22. Ibrahim, S.A. and Salameh, M.M. 2001. Simple and rapid method for screening antimicrobial activities of Bifidobacterium species of human isolates. J. Rapid Methods Autom. Microbiol. 9, 52-63.
23. Kondepudi, K.K., Ambalam, P., Nilsson, I., Wadstrom, T., and Ljungh, A. 2012. Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile. Anaerobe 18, 489-497.
24. Kuo, L.C., Teng, L.J., Yu, C.J., Ho, S.W., and Hsueh, P.R. 2004. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J. Clin. Microbiol. 42, 1759-1763.
25. Makras, L. and De Vuyst, L. 2006. The in vitro inhibition of Gram-negative pathogenic bacteria by bifidobacteria is caused by the production of organic acids. Int. Dairy J. 16, 1049-1057.
26. Marshall, J.C., Christou, N.V., and Meakins, J.L. 1993. The gastrointestinal tract. The "undrained abscess" of multiple organ failure. Ann. Surg. 218, 111-119.
27. Marteau, P. and Shanahan, F. 2003. Basic aspects and pharmacology of probiotics: An overview of pharmacokinetics mechanisms of action and side-effects. Best Pract. Res. Clin. Gastroenterol. 17, 725-740.
28. Matsumoto, T., Ishikawa, H., Tateda, K., Yaeshima, T., Ishibashi, N., and Yamaguchi, K. 2007. Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. J. Appl. Microbiol. 104, 672-680.
29. Navon-Venezia, S., Ben-Ami, R., and Carmeli, Y. 2005. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr. Opin. Infect. Dis. 18, 306-313.
30. Ohara, T. and Itoh, K. 2003. Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract. Int. Med. 42, 1072-1076.
31. O'Riordan, K. and Fitzgerald, G.F. 1998. Evaluation of bifidobacteria for the production of antimicrobial compounds and assessment of performance in cottage cheese at refrigeration temperature. J. Appl. Microbiol. 85, 103-114.
32. Parvez, S., Malik, K.A., Ah Kang, S., and Kim, H.Y. 2006. Probiotics and their fermented food products are beneficial for health. J. Appl. Microbiol. 100, 1171-1185.
33. Rodriguez, E., Arques, J.L., Rodriguez, R., Peiroten, A., Landete, J.M., and Medina, M. 2012. Antimicrobial properties of probiotic strains isolated from breast-fed infants. J. Funct. Foods 4, 542-551.
34. Servin, A.L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. 28, 405-440.
35. Shah, P.M. 2005. The need for new therapeutic agents: what is the pipeline? Clin. Microbiol. Infect. 11, 36-42.
36. Tissier, H. 1990. Ph. D. Thesis, University of Paris, Paris, France. Trottier, V., Segura, P.G., Namias, N., King, D., Pizano, L.R., and Schulman, C.I. 2007. Outcomes of Acinetobacter baumannii infection in critically I11 burned patients. J. Burn. Care Res. 28, 248-254.
37. Yildirim, Z. and Johnson, M.G. 1998. Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454. J. Food Prot. 61, 47-51.
38. Yildirim, Z., Winters, D.K., and Johnson, M.G. 1999. Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacterium bifidum NCFB 1454. J. Appl. Microbiol. 86, 45-54.